Dr. Jason King, Oxford Biotrans Chief Executive Officer & Founder
Jason has seventeen years’ start-up/SME experience covering global business development, business leadership and project management, primarily in the catalysis, chemicals and advanced materials sectors. Previously Jason was Vice President for Business Development with Avantium Technologies in the Netherlands and then Business Development Director of hte AG in Germany before leading the start-up of MatOx Ltd, an Oxford-based IP development and commercialization business focused on advanced materials, and working with biomaterials company Giltech Ltd as director of business development. Jason is a specialist in early-stage technology development/commercialization, collaborative research and development partnerships and technology licensing. Since 2013 he has been CEO of Oxford Biotrans, a spin-out company from the University of Oxford, which is commercialising novel routes to high-value chemicals using proprietary enzyme technology.He has an MA in Natural Sciences from the University of Cambridge and a PhD in chemistry from the same.